Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARSPECT: 99mTc-NTP 15-5 in Cartilage
NCT04481230Phase 1Completed
- Sponsor
- Centre Jean Perrin
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of 99mTc-NTP 15-5 in osteoarthritis (OA) (3 arms), sponsored by Centre Jean Perrin. Primary endpoints: Determination of the recommended dose of 99mTc-NTP 15-5 at Day 0 and Dose-limiting toxicity at 1 week. Started Nov 2020; status: completed.
02
Drugs
99mTc-NTP 15-5
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04481230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481230.